论文部分内容阅读
目的:探讨血清β2-微球蛋白(β2-microglobulin,β2-MG)对套细胞淋巴瘤(mantle-cell lymphoma,MCL)患者生存预后的影响,以及与MCL国际预后指数(MCL international prognostic index,MIPI)之间的关系。方法:回顾分析了61例MCL患者的临床资料,分析其异常的血清β2-MG表达是否影响患者预后。血清β2-MG表达水平与患者临床特征之间相关性分析采用Fisher精确检验法,预后的多因素分析采用COX比例风险回归模型。结果:MCL患者初次确诊的生化指标检查结果显示,61例患者中35例(57.4%)患者有血清β2-MG异常升高,并且与临床分期(P=0.011)、B症状(P=0.032)、骨髓受累(P<0.001)、乳酸脱氢酶(P=0.001)、白细胞计数(P=0.008)、Ki-67(P=0.010)及MIPI评分(P=0.005)显著相关。多因素分析显示,血清β2-MG是影响MCL患者预后的独立危险因素(P=0.022),并且在MIPI的中危组(4~5分)中,血清β2-MG异常升高的患者的总生存期显著短于血清β2-MG正常患者(P<0.001),而在低危组(0~3分)和高危组(6~11分)中差异无统计学意义。结论:血清β2-MG是影响MCL患者预后的独立危险因素,特别在MIPI评分中危组中血清β2-MG>2.5 mg/L患者的总生存期明显短于血清β2-MG≤2.5 mg/L者。
Objective: To investigate the effect of β2-microglobulin (β2-MG) on the prognosis of patients with mantle-cell lymphoma (MCL) and its relationship with the MCL international prognostic index (MIPI) )The relationship between. Methods: The clinical data of 61 patients with MCL were retrospectively analyzed. Whether the abnormal serum β2-MG expression affected the prognosis of patients was analyzed. Correlation analysis between serum β2-MG expression level and clinical characteristics of patients was performed by Fisher’s exact test and multivariate analysis of prognosis was performed by COX proportional hazards regression model. Results: The biochemical test results of the initial diagnosis in MCL patients showed that serum β2-MG was abnormally elevated in 35 patients (57.4%) of 61 patients and was significantly correlated with clinical stage (P = 0.011), B symptoms (P = 0.032) , Bone marrow involvement (P <0.001), lactate dehydrogenase (P = 0.001), white blood cell count (P = 0.008), Ki-67 (P = 0.010) and MIPI score (P = 0.005) Multivariate analysis showed that serum β2-MG was an independent risk factor affecting the prognosis of patients with MCL (P = 0.022), and in patients with moderate-risk MIPI (4 to 5), the total number of patients with abnormally elevated serum β2-MG The survival time was significantly shorter than that of normal serum β2-MG patients (P <0.001), but no significant difference was found between low risk group (0-3) and high risk group (6-11). Conclusion: Serum β2-MG is an independent risk factor for prognosis in patients with MCL. The overall survival of patients with serum β2-MG> 2.5 mg / L is significantly shorter than that of serum β2-MG≤2.5 mg / L By.